Robert K. Brooks, JD: Chairman, Chief Executive Officer
Robert Brooks serves as Founder, Chairman and Chief Executive Officer of the Company. Robert brings over 30 years of biotechnology, financial and legal experience. He previously founded and served as Chief Executive Officer of Radiance Bio, a company focused on Chimeric Antigen Receptor (CAR) T-cell therapy. In 2015, he founded and served as Chief Executive Officer of Aurora Biopharma, a biotechnology company with a mission to develop CAR T-cell therapy for solid tumors. In 2012, he founded and served as Chief Executive Officer of Medvax Technologies, a clinical stage biotechnology company focused on developing Dendritic Cell Cancer vaccines. In 2010, he founded and served as Chief Executive Officer of Metabogenix Technologies Inc. to research cancer metabolism. From 2000 to 2010, Mr. Brooks practiced corporate law, representing privately-held companies. From 1987 till 1999, he was employed in the financial industry, and involved in investment banking. He serves on the Board of Directors of Medtherapy, Inc., a start-up global cell and gene manufacturer.
He also is managing director of US Global Capital, LLC, a private investment company. He holds a Juris Doctorate degree from the University of Miami, Florida, and undergraduate Bachelor of Science degree, Cum Laude, in biology.
Ola Soderquist, CPA: Chief Financial Officer
Ola Soderquist serves as the Chief Financial Officer of the Company. He has served in CFO and other managerial capacities at Oxygen Therapy, Inc.; Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA)and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC). Ola is a multi-lingual senior finance professional poised to work globally and cross-functionally, particularly with complex projects involving business integration, systems implementation, continuous improvement, and process excellence. Ola’s managerial experience portfolio includes Start-ups, Private, Public, Venture Capital and Private Equity ownership. He obtained a BS and an MS in Accounting from Stockholm School of Economics and an MBA from Babson College – Franklin W. Olin Graduate School of Business.
A. Graham Pockley, PhD: (Interim) Chief Scientific Officer
Dr. A. Graham Pockley is CEO of Multimmune GmbH, Munich, Germany, a private clinical-stage biopharmaceutical company which has developed platform technologies for the treatment of cancers expressing membrane Hsp70. He was formerly Professor of Immunobiology at Nottingham Trent University, UK, Director of the John van Geest Cancer Research, and Founder and CEO of Chromocyte Limited, Sheffield, UK. Previously he directed the experimental transplantation program in the Professorial Surgical Unit at the Medical College of St. Bartholomew´s Hospital, London and later was appointed Professor of Immunobiology at the University of Sheffield before moving to Nottingham Trent University in 2012, with which he is currently Emeritus Professor. His research focus for the last 20 years has been on the development of innovative therapeutics and diagnostics in immuno-oncology. He has accumulated a portfolio of over 207 peer-reviewed publications.